Fall forest trail

Today is one of those ‘welcome to the frontier of cancer therapeutics, where innovation meets possibility’ moments.

In the realm of cutting-edge biotech, a new IO player has emerged from the north east, charting a course to change cancer treatment for the better.

This biotech company is navigating uncharted territory, exploring novel approaches to enhance T cell interactions, with a specific focus on overcoming T cell exhaustion – a common hurdle in advanced cancers which often limits our ability to mount a sustained immune response.

Who are they and what precisely are they doing differently?

To find out and continue reading our latest highlights on oncology new product development including commentary and analysis, BSB subscribers can log-in or you can click to access the content.

This content is restricted to subscribers

Posted by